コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ive bare-metal stents followed by 1 month of dual antiplatelet therapy.
2 et activation and aggregation in patients on dual antiplatelet therapy.
3 All patients received 1 month of dual antiplatelet therapy.
4 nd points when used with a 1-month course of dual antiplatelet therapy.
5 ave a higher risk of bleeding from prolonged dual antiplatelet therapy.
6 among smokers observed in trials evaluating dual antiplatelet therapy.
7 on in clinical practice, requiring prolonged dual antiplatelet therapy.
8 high risk for bleeding if they also receive dual antiplatelet therapy.
9 independently correlated with high RPR after dual antiplatelet therapy.
10 heparin remain unknown in an era of routine dual antiplatelet therapy.
11 a-blocker treatment, and a neutral effect of dual antiplatelet therapy.
12 as observed only in patients not adhering to dual antiplatelet therapy.
13 trial has proved this in patients receiving dual antiplatelet therapy.
14 associated with premature discontinuation of dual antiplatelet therapy.
15 are at-risk for premature discontinuation of dual antiplatelet therapy.
16 ted stent (DCS) or a BMS followed by 1-month dual antiplatelet therapy.
17 tensin receptor blockers, beta-blockers, and dual antiplatelet therapy.
18 different risks and benefits with prolonged dual antiplatelet therapy.
19 ing a feasible approach for patients needing dual antiplatelet therapy.
20 ompared with aspirin alone or short duration dual antiplatelet therapy.
21 9,644 participants to different durations of dual antiplatelet therapy.
22 thrombosis, and thus the need for prolonged dual-antiplatelet therapy.
23 bolytic status in 300 ACS patients receiving dual-antiplatelet therapy.
24 s 2 (40%) did not receive standard post-TAVI dual-antiplatelet therapy.
25 or clopidogrel, 0.17 (95% CI, 0.04-0.76) for dual antiplatelet therapy, 0.48 (95% CI, 0.22-1.04) for
26 of major hemorrhage was almost doubled with dual antiplatelet therapy (105 hemorrhages, 2.1% per yea
27 cantly reduced with aspirin and clopidogrel (dual antiplatelet therapy) (125 strokes; rate, 2.5% per
28 ight [4%] of 224) than among those receiving dual antiplatelet therapy (31 [15%] of 208; p<0.0001); N
29 increased among patients assigned to receive dual antiplatelet therapy (77 deaths in the group receiv
30 was particularly high in patients receiving dual antiplatelet therapy (adjusted HR, 5.21; 95% CI, 1.
34 commendation ("may be considered") to extend dual antiplatelet therapy after drug-eluting stent impla
35 recommendation is for at least 12 months of dual antiplatelet therapy after implantation of a drug-e
36 Approximately 10% of patients who receive dual antiplatelet therapy after percutaneous coronary in
38 t therapy with P2Y12 inhibitors alone versus dual-antiplatelet therapy after acute coronary syndromes
39 apy and the risk-benefit ratio for long-term dual-antiplatelet therapy after coronary stenting remain
40 patients received short-term (1 to 3 months) dual-antiplatelet therapy after the procedure and single
42 benefits and risks of 30 versus 12 months of dual antiplatelet therapy among patients undergoing coro
43 e is particularly high in patients receiving dual antiplatelet therapy and in the 1st year after stro
47 CH did not differ between patients receiving dual-antiplatelet therapy and those receiving aspirin mo
48 und -guided stenting, assiduous adherence to dual antiplatelet therapy, and adequate P2Y12 platelet r
50 -angiotensin system blockers, beta-blockers, dual antiplatelet therapy, and long-term cardiovascular
51 urrent era of drug-eluting stents, prolonged dual antiplatelet therapy, and potent P2Y12 inhibitors a
52 nts received coronary revascularization, 22% dual-antiplatelet therapy, and 71% high-dose statin ther
54 pirin in what has come to be commonly called dual antiplatelet therapy, are a mainstay of treatment f
55 /-7.9 years; 65% men; 75% diabetic) received dual antiplatelet therapy as a single loading dose (tica
56 Patients were randomized (1:1) to receive dual antiplatelet therapy (aspirin + clopidogrel [the cl
58 who received at least one coronary stent and dual antiplatelet therapy (aspirin and ticlopidine or cl
60 ients with diabetes on long-term (12 months) dual antiplatelet therapy (aspirin plus clopidogrel) wer
62 coronary intervention and were discharged on dual-antiplatelet therapy at 228 US hospitals in the Tre
64 ary stent implantation and were treated with dual antiplatelet therapy between July 1, 1994, and Apri
66 atelet Therapy (DAPT) Study, continuation of dual antiplatelet therapy beyond 12 months after coronar
67 n of patient benefit and harm from continued dual antiplatelet therapy beyond assessment of MI histor
68 y outcome at 2 years was 10.1% with 24-month dual-antiplatelet therapy compared with 10.0% with 6-mon
69 atelets exhibit increased reactivity despite dual antiplatelet therapy, compared with smaller platele
71 pite recent studies, the optimum duration of dual antiplatelet therapy (DAPT) after coronary drug-elu
74 the effect of 30 months versus 12 months of dual antiplatelet therapy (DAPT) after percutaneous coro
80 ant use of proton pump inhibitors (PPIs) and dual antiplatelet therapy (DAPT) for cardiovascular outc
83 practice guidelines recommend post-operative dual antiplatelet therapy (DAPT) in patients who undergo
84 de updates regarding the optimal duration of dual antiplatelet therapy (DAPT) in patients with acute
85 prolonged (24 months) vs short (</=6 months) dual antiplatelet therapy (DAPT) in patients with PAD un
92 among patients with DM participating in the Dual Antiplatelet Therapy (DAPT) Study as a prespecified
93 ndary analysis is derived from data from the Dual Antiplatelet Therapy (DAPT) Study, a multicenter tr
95 coagulation with a vitamin K antagonist plus dual antiplatelet therapy (DAPT) with a P2Y12 inhibitor
98 , and clinical significance of bleeding with dual antiplatelet therapy (DAPT), particularly over an e
99 eated with a vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT), yet this treatment lea
104 telet therapy, and in 3 of them discontinued dual antiplatelet therapy discontinuation had occurred t
106 drug-eluting stents, which require prolonged dual antiplatelet therapy due to the increased risk of l
107 ision tool (DAPT score) aids prescription of dual antiplatelet therapy duration in patients with or w
108 g late ischemic and bleeding risks to inform dual antiplatelet therapy duration showed modest accurac
110 educed myocardial infarctions with prolonged dual antiplatelet therapy, findings that support the new
114 let therapy compared with 10.0% with 6-month dual-antiplatelet therapy (hazard ratio, 0.98; 95% confi
115 aspirin alone vs. 113 in the group receiving dual antiplatelet therapy) (hazard ratio, 1.52; 95% CI,
116 cing runs, earlier date of procedure, and no dual antiplatelet therapy; high pre-TAVR aortic peak gra
117 5, P=0.04), and premature discontinuation of dual antiplatelet therapy (HR=2.67, P=0.003); high plate
118 olled trials are needed to establish whether dual antiplatelet therapy improves clinical outcome in h
119 x vivo platelet aggregation before and after dual antiplatelet therapy in individuals (n=565) from th
121 udy was to determine the possible benefit of dual antiplatelet therapy in patients with prior myocard
122 tion could be associated with high RPR after dual antiplatelet therapy in patients with stable corona
124 ed the impact of up to 6 versus 24 months of dual-antiplatelet therapy in a broad all-comers patient
126 f increased use of clopidogrel, statins, and dual antiplatelet therapy, in addition to the introducti
127 esidual platelet reactivity (high RPR) after dual antiplatelet therapy is associated with increased c
131 coated with biolimus-A9 followed by 1-month dual antiplatelet therapy is safer and more effective th
134 ed events while patients received background dual antiplatelet therapies (ITT: 7.9% vs. 11.9%, p = 0.
135 tion of DAPT after the procedure, and longer dual antiplatelet therapy (L-DAPT) was defined as the pe
137 ompared with aspirin alone or short duration dual antiplatelet therapy (</=6 months), continued treat
138 studies suggest that early administration of dual antiplatelet therapy may be better than monotherapy
140 ective comparison of the current standard of dual antiplatelet therapy of aspirin with clopidogrel ve
141 ed to assess the effect of extended duration dual antiplatelet therapy on mortality by doing a meta-a
143 mostly been studied in addition to aspirin; dual-antiplatelet therapy proved superiority compared wi
144 xtended duration versus no or short duration dual antiplatelet therapy, published before Oct 1, 2014.
145 ared with 12 months of therapy, 30 months of dual antiplatelet therapy reduced the risk of stent thro
146 s with critical limb ischemia, perioperative dual antiplatelet therapy reduces biomarkers of atheroth
151 R1) gene to be most strongly associated with dual antiplatelet therapy response (P=7.66x10(-9)).
152 ions of DAPT after DES implantation: shorter dual antiplatelet therapy (S-DAPT) was defined as the pe
155 aclitaxel-eluting stent and prasugrel to the Dual Antiplatelet Therapy Study (DAPT) that compared 12
165 2]) but was greater among patients receiving dual-antiplatelet therapy than among those receiving clo
166 Among stented patients who were treated with dual antiplatelet therapy, there was a mortality reducti
167 Patients in trials evaluating stents or dual antiplatelet therapy to prevent coronary stent thro
168 mly assigned patients with an indication for dual antiplatelet therapy to receive clopidogrel in comb
169 g would represent a paradigm shift away from dual antiplatelet therapy toward long-term triple antith
170 ntation Followed by Six- Versus Twelve-Month Dual Antiplatelet Therapy) trial was a 1:1 randomized, m
172 fatal hemorrhages (9 in the group receiving dual antiplatelet therapy vs. 4 in the group receiving a
173 with zotarolimus-eluting stents, 3 months of dual antiplatelet therapy was noninferior to 12 months f
176 icoagulation with warfarin, as compared with dual antiplatelet therapy, was associated with a decreas
177 agulation (both NOACs and warfarin), but not dual antiplatelet therapy, was effective in prevention o
180 botic therapy (ie, oral anticoagulation plus dual antiplatelet therapy) were independent predictors o
182 res are performed annually in the U.S., with dual-antiplatelet therapy, which includes the use of bot
183 peratively (days 5 and 2) despite continuing dual antiplatelet therapy while undergoing multidigit re
184 ted heparin during the procedure followed by dual antiplatelet therapy with aspirin (indefinitely) an
190 stent (DES) implantation require additional dual antiplatelet therapy with aspirin and clopidogrel.
191 )+aspirin+clopidogrel, VKA+antiplatelet, and dual antiplatelet therapy with aspirin+clopidogrel.
193 appeared to derive significant benefit from dual antiplatelet therapy with clopidogrel plus aspirin.
196 med a post hoc analysis of the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAP
198 n the large-scale, prospective Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents study
199 rolled in the ADAPT-DES study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) acco
200 as performed in the ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) regi
201 The prospective ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) stud
204 , multicenter ADAPT-DES study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) were
205 es (PROMETHEUS, ADAPT-DES [the Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents], THI
208 lementation after loading and maintenance of dual antiplatelet therapy with ticagrelor and the influe
212 coronary syndromes who were mostly receiving dual antiplatelet therapy, with conflicting results on e
213 ne coronary stenting and completed 1 year of dual antiplatelet therapy without major bleeding or isch
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。